1. |
Cheung KL. Endocrine therapy for breast cancer: an overview[J]. Breast, 2007, 16(4): 327-343.
|
2. |
Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer[J]. Oncology (Williston Park), 2012, 26(8): 688-694, 696.
|
3. |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet,2005, 365(9472): 1687-1717.
|
4. |
Goldhirsch A, Colleoni RD, Gelber M. Endocrine therapy of breast cancer[J]. Oncol, 2002, 13(4): 61–68.
|
5. |
Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer[J]. Endocr Relat Cancer, 2014, 21(3): R235-R246.
|
6. |
García-Becerra R, Santos N, Díaz L, et al. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs andgenetically based resistance[J]. Int J Mol Sci, 2012, 14(1): 108-145.
|
7. |
Cheng SB, Quinn JA, Graeber CT, et al. Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway[J]. J Biol Chem, 2011, 286(25): 22441-22455.
|
8. |
Nass N, Kalinski T. Tamoxifen resistance: from cell culture experiments towards novel biomarkers[J]. Pathol Res Pract, 2015, 211(3): 189-197.
|
9. |
Li L, Haynes MP, Bender JR. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells[J]. Proc Natl Acad Sci USA, 2003, 100(8): 4807-4812.
|
10. |
Wang Z, Zhang X, Shen P, et al. Identifcation, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66[J]. Biochem Biophys Res Commun, 2005, 336(4): 1023-1027.
|
11. |
Hirata S, Shoda T, Kato J, et al. Isoform/variant mRNAs for sex steroid hormone receptors in humans[J]. Trends Endocrinol Metab, 2003, 14(3): 124-129.
|
12. |
Deng H, Huang X, Fan J, et al. A variant of estrogen receptoralpha, ER-alpha36 is expressed in human gastric cancer and is highlycorrelated with lymph node metastasis[J]. Oncol Rep, 2010, 24(1): 171-176.
|
13. |
Greene GL, Gilna P, Waterfeld M, et al. Sequence and expression of human estrogen receptor complementary DNA[J]. Science, 1986, 231(4742): 1150-1154.
|
14. |
Kong EH, Pike AC, Hubbard RE. Structure and mechanism of the oestrogen receptor[J]. Biochem Soc Trans, 2003, 31(1): 56-59.
|
15. |
Rao J, Jiang X, Wang Y, et al. Advances in the understanding of the structure and function of ER-α36, a novel variant of human estrogen receptor-alpha[J]. J Steroid Biochem Mol Biol, 2011, 127(3-5): 231-237.
|
16. |
Wang Z, Zhang X, Shen P, et al. A variant of estrogen receptor- alpha, hER-alpha36: transduction of estrogen- and antiestrogendependentmembrane- initiated mitogenic signaling[J]. Proc Natl Acad Sci USA, 2006, 103(24): 9063-9068.
|
17. |
Ma d a i o R A , S p a l l e t t a G , C r a v e l l o L , e t a l . Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions[J]. World J Clin Oncol, 2014, 5(5): 990-1001.
|
18. |
Zhang X, Wang ZY. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity[J]. Endocrinology, 2013, 154(6): 1990-1998.
|
19. |
Vranic S, Gatalica Z, Deng H, et al. ER-α36, a novel isoform of ER- α66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast[J]. J Clin Pathol, 2011, 64(1): 54-57.
|
20. |
Lin SL, Yan LY, Zhang XT, et al. ER-alpha36, a variant of ERalpha, promotes tamoxifen agonist action in endometrial cancer cells via theMAPK/ERK and PI3K/Akt pathways[J]. PLoS One, 2010, 5(2): e9013.
|
21. |
Zhang X, Ding L, Kang L, e t a l . E s t r o g e n receptoralpha 36 mediates mitogenic antiestrogen signaling in ERnegative breast cancer cells[J]. PLoS One, 2012, 7(1): e30174.
|
22. |
Wang X, Hills LB, Huang YH. Lipid and protein co-regulation of PI3K effectors Akt and Itk in lymphocytes[J]. Front Immunol, 2015(6): 117.
|
23. |
Xia B, Tian C, Guo S, et al. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia[J]. Leuk Res, 2015, 39(1): 92-99.
|
24. |
Lee LM, Cao J, Deng H, et al. ER-alpha36, a novel variant of ERalpha, is expressed in ER-positive and -negative human breast carcinomas[J]. Anticancer Res, 2008, 28(1B): 479-483.
|
25. |
Zhang XT, Kang LG, Ding L, et al. A positive feedback loop of ER-α3 6 /EGFR promot e s ma l i gnant g rowth of ERnegative breast cancer cells[J]. Oncogene, 2011, 30(7): 770-780.
|
26. |
Tu BB, Lin SL, Yan LY, et al. ER-α36, a novel variant of estrogen receptor α, is involved in EGFR-related carcino-genesis in endometrial cancer[J]. Am J Obstet Gynecol, 2011, 205(3): e1-e6.
|
27. |
Chung YL, Sheu ML, Yang SC, et al. Resistance to tamoxifen induced apoptosis is associated with direct interaction between Her2/neu andcell membrane estrogen receptor in breast cancer[J]. Cancer, 2002, 97(3): 306-312.
|
28. |
Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer[J]. J Natl Cancer Inst, 2004, 96(12): 926-935.
|
29. |
Kang L, Guo Y, Zhang X, et al. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells[J]. J Steroid Biochem Mol Biol, 2011, 127(3/4/5): 262-268.
|
30. |
Li G, Zhang J, Jin K, et al. Estrogen receptor-alpha 36 is involved in development of acquired tamoxifen resistance via regulating the growth status Switch in breast cancer cells[J]. Mol Oncol, 2013, 7(3): 611-624.
|
31. |
Deng H, Yin L, Zhang XT, et al. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/ progenitor cells[J]. J Steroid Biochem Mol Biol, 2014, 144(B): 417-426.
|
32. |
Yin L, Zhang XT, Bian XW, et al. Disruption of the ER-a36-EGFR/ HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells[J]. PLoS One, 2014, 9(9): e107369.
|